{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:03:31Z","timestamp":1760058211601,"version":"build-2065373602"},"reference-count":97,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T00:00:00Z","timestamp":1742342400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>The use of antiplatelet agents is essential in percutaneous coronary interventions, both periprocedurally and in the post-interventional period. Procedural antiplatelet therapy, aiming to limit ischemic complications, is mostly administered with oral agents, including aspirin and P2Y12 inhibitors. However, there are several limitations in the use of oral P2Y12 inhibitors, including their difficult administration in patients presenting with cardiogenic shock and their relatively slower onset of action, leaving a significant period of the procedure with a suboptimal antiplatelet effect. These pitfalls could be avoided with the use of cangrelor, the only available intravenous P2Y12 inhibitor, which has a rapid onset and offset antiplatelet effect, as well as a favorable pharmacological profile. The use of cangrelor has been increasing in recent years, with several studies aiming to determine what the optimal patient phenotype to receive such treatment ultimately is and how its use could be adjunctive to oral P2Y12 inhibitors. Therefore, the aim of this review is to provide an overview of the pharmacological profile of cangrelor and an update regarding the clinical evidence supporting its use, as well as to discuss the optimal patient phenotype, related clinical algorithms, and future implications for larger implementation of this agent into everyday clinical practice.<\/jats:p>","DOI":"10.3390\/ph18030432","type":"journal-article","created":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T07:48:37Z","timestamp":1742370517000},"page":"432","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Phenotyping the Use of Cangrelor in Percutaneous Coronary Interventions"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0401-9473","authenticated-orcid":false,"given":"Nikolaos","family":"Pyrpyris","sequence":"first","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyriakos","family":"Dimitriadis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8986-2704","authenticated-orcid":false,"given":"Konstantinos G.","family":"Kyriakoulis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4150-5286","authenticated-orcid":false,"given":"Stergios","family":"Soulaidopoulos","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1100-7430","authenticated-orcid":false,"given":"Panagiotis","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2726-9520","authenticated-orcid":false,"given":"Aggelos","family":"Papanikolaou","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5645-662X","authenticated-orcid":false,"given":"Nikolaos G.","family":"Baikoussis","sequence":"additional","affiliation":[{"name":"Department of Cardiac Surgery, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexios","family":"Antonopoulos","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0706-4424","authenticated-orcid":false,"given":"Konstantinos","family":"Aznaouridis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7636-6725","authenticated-orcid":false,"given":"Konstantinos","family":"Tsioufis","sequence":"additional","affiliation":[{"name":"First Department of Cardiology, School of Medicine, National and Kapodistrian University of Athens, Hippokration General Hospital, 115 27 Athens, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,19]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMra071014","article-title":"Platelet Activation and Atherothrombosis","volume":"357","author":"Patrono","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"e1371","DOI":"10.4244\/EIJ-D-21-00904","article-title":"Antiplatelet Therapy after Percutaneous Coronary Intervention","volume":"17","author":"Angiolillo","year":"2022","journal-title":"EuroIntervention"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.jacc.2022.11.041","article-title":"P2Y12 Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions","volume":"81","author":"Gragnano","year":"2023","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/ehjcvp\/pvac071","article-title":"Efficacy and Safety of P2Y12 Inhibitor Monotherapy after Complex PCI: A Collaborative Systematic Review and Meta-Analysis","volume":"9","author":"Nicolas","year":"2023","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e022125","DOI":"10.1161\/JAHA.121.022125","article-title":"Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives","volume":"10","author":"Steg","year":"2021","journal-title":"J. Am. Heart Assoc."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI Guideline for Coronary Artery Revascularization","volume":"79","author":"Lawton","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1007\/s40265-013-0126-z","article-title":"Pharmacology of the New P2Y12 Receptor Inhibitors: Insights on Pharmacokinetic and Pharmacodynamic Properties","volume":"73","author":"Ferri","year":"2013","journal-title":"Drugs"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1871525711311020005","article-title":"P2Y12 Inhibitors: Pharmacologic Mechanism and Clinical Relevance","volume":"11","author":"Secco","year":"2013","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1161\/01.ATV.0000012805.49079.23","article-title":"Role of ADP Receptor P2Y 12 in Platelet Adhesion and Thrombus Formation in Flowing Blood","volume":"22","author":"Remijn","year":"2002","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"394","DOI":"10.7326\/0003-4819-129-5-199809010-00009","article-title":"The Antiplatelet Effects of Ticlopidine and Clopidogrel","volume":"129","author":"Sharis","year":"1998","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11239-011-0667-5","article-title":"P2Y12 Platelet Inhibition in Clinical Practice","volume":"33","author":"Damman","year":"2012","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1177\/0091270009344986","article-title":"Pharmacokinetics and Pharmacodynamics of a Bolus and Infusion of Cangrelor: A Direct, Parenteral P2Y12 Receptor Antagonist","volume":"50","author":"Akers","year":"2010","journal-title":"J. Clin. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1586\/14779072.2013.837701","article-title":"Cangrelor: A Review on Pharmacology and Clinical Trial Development","volume":"11","author":"Franchi","year":"2013","journal-title":"Expert. Rev. Cardiovasc. Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"16108","DOI":"10.1074\/jbc.M809780200","article-title":"The P2Y12 Antagonists, 2-Methylthioadenosine 5\u2019-Monophosphate Triethylammonium Salt and Cangrelor (ARC69931MX), Can Inhibit Human Platelet Aggregation through a Gi-Independent Increase in CAMP Levels","volume":"284","author":"Srinivasan","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Xiang, B., Zhang, G., Ren, H., Sunkara, M., Morris, A.J., Gartner, T.K., Smyth, S.S., and Li, Z. (2012). The P2Y12 Antagonists, 2MeSAMP and Cangrelor, Inhibit Platelet Activation through P2Y12\/Gi-Dependent Mechanism. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0051037"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1161\/01.RES.0000264509.36234.51","article-title":"Clinical Aspects of Platelet Inhibitors and Thrombus Formation","volume":"100","author":"Meadows","year":"2007","journal-title":"Circ. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1016\/j.jacc.2017.01.028","article-title":"Potent P2Y 12 Inhibitors in Men Versus Women","volume":"69","author":"Lau","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1055\/s-0037-1615596","article-title":"Open Multicentre Study of the P2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes","volume":"85","author":"Storey","year":"2001","journal-title":"Thromb. Haemost."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"689.e1","DOI":"10.1016\/j.ahj.2005.11.014","article-title":"Initial Experience with an Intravenous P2Y12 Platelet Receptor Antagonist in Patients Undergoing Percutaneous Coronary Intervention: Results from a 2-Part, Phase II, Multicenter, Randomized, Placebo- and Active-Controlled Trial","volume":"151","author":"Greenbaum","year":"2006","journal-title":"Am. Heart J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1056\/NEJMoa0908629","article-title":"Intravenous Platelet Blockade with Cangrelor during PCI","volume":"361","author":"Bhatt","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/heartjnl-2012-303103","article-title":"A Novel Approach to Systematically Implement the Universal Definition of Myocardial Infarction: Insights from the CHAMPION PLATFORM Trial","volume":"99","author":"Leonardi","year":"2013","journal-title":"Heart"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1056\/NEJMoa0908628","article-title":"Platelet Inhibition with Cangrelor in Patients Undergoing PCI","volume":"361","author":"Harrington","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ahj.2011.11.001","article-title":"Reduced Immediate Ischemic Events with Cangrelor in PCI: A Pooled Analysis of the CHAMPION Trials Using the Universal Definition of Myocardial Infarction","volume":"163","author":"White","year":"2012","journal-title":"Am. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1056\/NEJMoa1300815","article-title":"Effect of Platelet Inhibition with Cangrelor during PCI on Ischemic Events","volume":"368","author":"Bhatt","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/j.jcin.2016.06.046","article-title":"Efficacy and Safety of Cangrelor in Preventing Periprocedural Complications in Patients With Stable Angina and Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention","volume":"9","author":"Abtan","year":"2016","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1161\/CIRCULATIONAHA.115.017300","article-title":"Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention","volume":"133","author":"Bhatt","year":"2016","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jcin.2014.09.025","article-title":"Outcomes With Cangrelor Versus Clopidogrel on a Background of Bivalirudin","volume":"8","author":"White","year":"2015","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jacc.2013.10.022","article-title":"Impact of Intraprocedural Stent Thrombosis During Percutaneous Coronary Intervention","volume":"63","author":"Stone","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1016\/S0140-6736(13)61615-3","article-title":"Effect of Cangrelor on Periprocedural Outcomes in Percutaneous Coronary Interventions: A Pooled Analysis of Patient-Level Data","volume":"382","author":"Steg","year":"2013","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1093\/ehjcvp\/pvz002","article-title":"Clinical Use of Cangrelor: Nationwide Experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR)","volume":"5","author":"Lagerqvist","year":"2019","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"3197512","DOI":"10.1155\/2023\/3197512","article-title":"Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study","volume":"2023","author":"Thim","year":"2023","journal-title":"Cardiol. Res. Pract."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s11239-024-02970-7","article-title":"Intravenous Antiplatelet Therapy in Patients with ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","volume":"57","author":"Silverio","year":"2024","journal-title":"J. Thromb. Thrombolysis"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.thromres.2007.05.020","article-title":"Transitioning Patients from Cangrelor to Clopidogrel: Pharmacodynamic Evidence of a Competitive Effect","volume":"121","author":"Steinhubl","year":"2008","journal-title":"Thromb. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1538-7836.2008.03020.x","article-title":"The Reversible P2Y12 Antagonist Cangrelor Influences the Ability of the Active Metabolites of Clopidogrel and Prasugrel to Produce Irreversible Inhibition of Platelet Function","volume":"6","author":"DOVLATOVA","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/phar.1477","article-title":"Ticagrelor: Pharmacokinetics, Pharmacodynamics, Clinical Efficacy, and Safety","volume":"34","author":"Dobesh","year":"2014","journal-title":"Pharmacother. J. Human. Pharmacol. Drug Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1161\/CIRCULATIONAHA.118.038317","article-title":"Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment\u2013Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention","volume":"139","author":"Franchi","year":"2019","journal-title":"Circulation"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.jcin.2022.10.034","article-title":"Cangrelor in Patients With Coronary Artery Disease Pretreated With Ticagrelor","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_39","first-page":"101202","article-title":"Risk of Bleeding Among Cangrelor-Treated Patients Administered Upstream P2Y12 Inhibitor Therapy: The CAMEO Registry","volume":"3","author":"Rymer","year":"2024","journal-title":"J. Soc. Cardiovasc. Angiogr. Interv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"oead076","DOI":"10.1093\/ehjopen\/oead076","article-title":"Safety of Cangrelor and Transition to Oral P2Y12 Inhibitors in Patients Undergoing Percutaneous Coronary Intervention: The ARCANGELO Study","volume":"3","author":"Capranzano","year":"2023","journal-title":"Eur. Heart J. Open"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2528","DOI":"10.1016\/j.jcin.2023.08.009","article-title":"Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention","volume":"16","author":"Franchi","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.carrev.2024.09.010","article-title":"ANOCA Updated: From Pathophysiology to Modern Clinical Practice","volume":"71","author":"Dimitriadis","year":"2024","journal-title":"Cardiovasc. Revascularization Med."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Pyrpyris, N., Dimitriadis, K., Iliakis, P., Theofilis, P., Beneki, E., Terentes-Printzios, D., Sakalidis, A., Antonopoulos, A., Aznaouridis, K., and Tsioufis, K. (2024). Hypothermia for Cardioprotection in Acute Coronary Syndrome Patients: From Bench to Bedside. J. Clin. Med., 13.","DOI":"10.3390\/jcm13185390"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"326","DOI":"10.21037\/atm.2017.06.27","article-title":"The Role of Reactive Oxygen Species in the Pathophysiology of Cardiovascular Diseases and the Clinical Significance of Myocardial Redox","volume":"5","author":"Moris","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1161\/ATVBAHA.109.189753","article-title":"C-Jun DNAzymes Inhibit Myocardial Inflammation, ROS Generation, Infarct Size, and Improve Cardiac Function After Ischemia-Reperfusion Injury","volume":"29","author":"Luo","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.carpath.2007.12.013","article-title":"Cardiac Oxidative Stress and Remodeling Following Infarction: Role of NADPH Oxidase","volume":"18","author":"Zhao","year":"2009","journal-title":"Cardiovasc. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"e004373","DOI":"10.1161\/CIRCINTERVENTIONS.116.004373","article-title":"Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment\u2013Elevation Myocardial Infarction Patients","volume":"10","author":"Bulluck","year":"2017","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1093\/eurheartj\/ehab775","article-title":"Coronary Flow Reserve and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis","volume":"43","author":"Kelshiker","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e033596","DOI":"10.1161\/JAHA.123.033596","article-title":"Impact of Coronary Microvascular Dysfunction on Functional Left Ventricular Remodeling and Diastolic Dysfunction","volume":"13","author":"Aldujeli","year":"2024","journal-title":"J. Am. Heart Assoc."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1161\/CIRCULATIONAHA.116.022603","article-title":"Comparative Prognostic Utility of Indexes of Microvascular Function Alone or in Combination in Patients With an Acute ST-Segment\u2013Elevation Myocardial Infarction","volume":"134","author":"Carrick","year":"2016","journal-title":"Circulation"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1016\/j.jacc.2007.08.062","article-title":"Predictive Value of the Index of Microcirculatory Resistance in Patients With ST-Segment Elevation Myocardial Infarction","volume":"51","author":"Fearon","year":"2008","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/ccd.27529","article-title":"Prognostic Value of the Index of Microcirculatory Resistance after Percutaneous Coronary Intervention in Patients with Non-ST-segment Elevation Acute Coronary Syndrome","volume":"92","author":"Murai","year":"2018","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Canu, M., Khouri, C., Marliere, S., Vautrin, E., Piliero, N., Ormezzano, O., Bertrand, B., Bouvaist, H., Riou, L., and Djaileb, L. (2022). Prognostic Significance of Severe Coronary Microvascular Dysfunction Post-PCI in Patients with STEMI: A Systematic Review and Meta-Analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0268330"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jcmg.2018.02.018","article-title":"Index of Microcirculatory Resistance as a Tool to Characterize Microvascular Obstruction and to Predict Infarct Size Regression in Patients With STEMI Undergoing Primary PCI","volume":"12","author":"Alkhalil","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1016\/j.jcin.2023.08.030","article-title":"The Index of Microcirculatory Resistance After Primary PCI","volume":"16","author":"Zimmermann","year":"2023","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.jacc.2021.08.017","article-title":"Microvascular Resistance Reserve for Assessment of Coronary Microvascular Function","volume":"78","author":"Pijls","year":"2021","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jcin.2024.03.024","article-title":"The Impact of Microvascular Resistance Reserve on the Outcome of Patients With STEMI","volume":"17","author":"Tsai","year":"2024","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_58","first-page":"9781","article-title":"The Effect of Ticagrelor on Myocardial Microcirculation, Cardiac Function, and Adverse Cardiovascular Events in STEMI Patients after PCI","volume":"27","author":"Liu","year":"2023","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/heartjnl-2022-321868","article-title":"Effects of Ticagrelor and Prasugrel on Coronary Microcirculation in Elective Percutaneous Coronary Intervention","volume":"110","author":"Mangiacapra","year":"2024","journal-title":"Heart"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"e964","DOI":"10.4244\/EIJV12I8A159","article-title":"Randomised Trial to Compare a Protective Effect of Clopidogrel Versus TIcagrelor on Coronary Microvascular Injury in ST-Segment Elevation Myocardial Infarction (CV-TIME Trial)","volume":"12","author":"Park","year":"2016","journal-title":"EuroIntervention"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e008105","DOI":"10.1161\/CIRCINTERVENTIONS.119.008105","article-title":"Comparison of the Effects of Ticagrelor and Clopidogrel on Microvascular Dysfunction in Patients With Acute Coronary Syndrome Using Invasive Physiologic Indices","volume":"12","author":"Park","year":"2019","journal-title":"Circ. Cardiovasc. Interv."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Qiu, X., Li, X., Fu, K., Chen, W., and Chen, W. (2023). The Effect of Ticagrelor on Coronary Microvascular Function after PCI in Patients with ACS Compared to Clopidogrel: A Systematic Review and Meta-Analysis. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0289243"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Li, Y., Ye, Z., Guo, Z., Xie, E., Wang, M., Zhao, X., Liu, M., Li, P., Yu, C., and Gao, Y. (2023). Ticagrelor vs. Clopidogrel for Coronary Microvascular Dysfunction in Patients with STEMI: A Meta-Analysis of Randomized Controlled Trials. Front. Cardiovasc. Med., 10.","DOI":"10.3389\/fcvm.2023.1102717"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1161\/CIRCULATIONAHA.118.035931","article-title":"Evaluation of Microvascular Injury in Revascularized Patients With ST-Segment\u2013Elevation Myocardial Infarction Treated With Ticagrelor Versus Prasugrel","volume":"139","author":"Janssens","year":"2019","journal-title":"Circulation"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jacc.2013.09.067","article-title":"Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome","volume":"63","author":"Bonello","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s10741-024-10445-3","article-title":"The Role of Coronary Microcirculation in Heart Failure with Preserved Ejection Fraction: An Unceasing Odyssey","volume":"30","author":"Dimitriadis","year":"2024","journal-title":"Heart Fail. Rev."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.atherosclerosis.2018.05.053","article-title":"Ticagrelor, a P2Y12 Antagonist, Attenuates Vascular Dysfunction and Inhibits Atherogenesis in Apolipoprotein-E-Deficient Mice","volume":"275","author":"Ganbaatar","year":"2018","journal-title":"Atherosclerosis"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jacbts.2018.05.005","article-title":"Ticagrelor Reduces Thromboinflammatory Markers in Patients With Pneumonia","volume":"3","author":"Sexton","year":"2018","journal-title":"JACC Basic. Transl. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/SHK.0b013e3181f48987","article-title":"Adenosine Diphosphate Receptor Antagonist Clopidogrel Sulfate Attenuates LPS-Induced Systemic Inflammation in a Rat Model","volume":"35","author":"Hagiwara","year":"2011","journal-title":"Shock"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Mansour, A., Bachelot-Loza, C., Nesseler, N., Gaussem, P., and Gouin-Thibault, I. (2020). P2Y12 Inhibition beyond Thrombosis: Effects on Inflammation. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21041391"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.mvr.2018.05.006","article-title":"Ticagrelor Protects against AngII-Induced Endothelial Dysfunction by Alleviating Endoplasmic Reticulum Stress","volume":"119","author":"Wang","year":"2018","journal-title":"Microvasc. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s11010-020-03731-9","article-title":"Ticagrelor Reverses the Mitochondrial Dysfunction through Preventing Accumulated Autophagosomes-Dependent Apoptosis and ER Stress in Insulin-Resistant H9c2 Myocytes","volume":"469","author":"Olgar","year":"2020","journal-title":"Mol. Cell Biochem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jcin.2017.05.064","article-title":"Comparison of Ticagrelor Versus Prasugrel for Inflammation, Vascular Function, and Circulating Endothelial Progenitor Cells in Diabetic Patients With Non\u2013ST-Segment Elevation Acute Coronary Syndrome Requiring Coronary Stenting","volume":"10","author":"Jeong","year":"2017","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1093\/eurheartj\/ehz917","article-title":"Effects of Clopidogrel vs. Prasugrel vs. Ticagrelor on Endothelial Function, Inflammatory Parameters, and Platelet Function in Patients with Acute Coronary Syndrome Undergoing Coronary Artery Stenting: A Randomized, Blinded, Parallel Study","volume":"41","author":"Schnorbus","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jcin.2018.04.022","article-title":"Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers","volume":"11","author":"Ariotti","year":"2018","journal-title":"JACC Cardiovasc. Interv."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/1074248419841640","article-title":"Ticagrelor Does Not Improve Endothelial Dysfunction in Stable Survivors of Acute Coronary Syndrome","volume":"24","author":"Lim","year":"2019","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Guan, B., Zhao, L., Ma, D., Fan, Y., Zhang, H., Wang, A., and Xu, H. (2022). The Effect of Ticagrelor on Endothelial Function Compared to Prasugrel, Clopidogrel, and Placebo: A Systematic Review and Meta-Analysis. Front. Cardiovasc. Med., 8.","DOI":"10.3389\/fcvm.2021.820604"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1177\/1074248412467692","article-title":"Platelet P2Y 12 Blockers Confer Direct Postconditioning-Like Protection in Reperfused Rabbit Hearts","volume":"18","author":"Yang","year":"2013","journal-title":"J. Cardiovasc. Pharmacol. Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10557-012-6436-7","article-title":"Two Classes of Anti-Platelet Drugs Reduce Anatomical Infarct Size in Monkey Hearts","volume":"27","author":"Yang","year":"2013","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s10557-015-6633-2","article-title":"Cangrelor-Mediated Cardioprotection Requires Platelets and Sphingosine Phosphorylation","volume":"30","author":"Cohen","year":"2016","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1055\/s-0039-1688789","article-title":"Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial","volume":"119","author":"Ubaid","year":"2019","journal-title":"Thromb. Haemost."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1161\/CIRCULATIONAHA.124.068938","article-title":"Effect of Cangrelor on Infarct Size in ST-Segment\u2013Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)","volume":"150","author":"Bulluck","year":"2024","journal-title":"Circulation"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.resuscitation.2019.02.008","article-title":"Cangrelor in Cardiogenic Shock and after Cardiopulmonary Resuscitation: A Global, Multicenter, Matched Pair Analysis with Oral P2Y12 Inhibition from the IABP-SHOCK II Trial","volume":"137","author":"Droppa","year":"2019","journal-title":"Resuscitation"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.cardfail.2024.08.003","article-title":"The Use of Cangrelor in Cardiogenic Shock: Insights from the CAMEO Registry","volume":"30","author":"RYMER","year":"2024","journal-title":"J. Card. Fail."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1177\/1060028021994621","article-title":"Clinical Use of Cangrelor After Percutaneous Coronary Intervention in Patients Requiring Mechanical Circulatory Support","volume":"55","author":"Katz","year":"2021","journal-title":"Ann. Pharmacother."},{"key":"ref_86","first-page":"1269","article-title":"Cangrelor for Comatose Survivors of Out-of-Hospital Cardiac Arrest Undergoing Percutaneous Coronary Intervention: The CANGRELOR-OHCA Study","volume":"18","author":"Kordis","year":"2023","journal-title":"EuroIntervention"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ehjacc\/zuad041","article-title":"Cangrelor in Patients with Percutaneous Coronary Intervention for Acute Myocardial Infarction after Cardiac Arrest and\/or with Cardiogenic Shock","volume":"12","author":"Zeymer","year":"2023","journal-title":"Eur. Heart J. Acute Cardiovasc. Care"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1710261","article-title":"PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock","volume":"377","author":"Thiele","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"D\u2019Andria Ursoleo, J., Baldetti, L., Pieri, M., Nardelli, P., Altizio, S., Ajello, S., and Scandroglio, A.M. (2024). Anti-Platelet Therapy with Cangrelor in Cardiogenic Shock Patients: A Systematic Review and Single-Arm Meta-Analysis. Medicina, 60.","DOI":"10.3390\/medicina60122092"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e1309","DOI":"10.4244\/EIJ-D-24-00203","article-title":"Cangrelor versus Crushed Ticagrelor in Patients with Acute Myocardial Infarction and Cardiogenic Shock: Rationale and Design of the Randomised, Double-Blind DAPT-SHOCK-AMI Trial","volume":"20","author":"Motovska","year":"2024","journal-title":"EuroIntervention"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1001\/jama.2011.2002","article-title":"Bridging Antiplatelet Therapy With Cangrelor in Patients Undergoing Cardiac Surgery","volume":"307","author":"Angiolillo","year":"2012","journal-title":"JAMA"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"e437","DOI":"10.1055\/s-0040-1721504","article-title":"Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience","volume":"4","author":"Rossini","year":"2020","journal-title":"TH Open"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.ahjo.2022.100122","article-title":"Cangrelor in STEMI as a Bridge to CABG- a Mini-Case Series","volume":"13","author":"Shrestha","year":"2022","journal-title":"Am. Heart J. Plus Cardiol. Res. Pract."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s40119-018-0113-2","article-title":"A Novel Bridging Strategy for Patients Undergoing Emergent Non-Cardiac Surgery with a Recent Coronary Stent","volume":"7","author":"Bruck","year":"2018","journal-title":"Cardiol. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.repc.2021.08.006","article-title":"Cangrelor as Antiplatelet Bridging Therapy in Non-Cardiac Surgery after Percutaneous Coronary Intervention\u2013First-Time Use in Portugal","volume":"41","author":"Fialho","year":"2022","journal-title":"Rev. Port. Cardiol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"suac121.293","DOI":"10.1093\/eurheartjsupp\/suac121.293","article-title":"330 Intravenous cangrelor infusion in high bleeding risk patients undergoing percutaneous coronary intervention: Preliminary results of the icarus registry","volume":"24","author":"Benenati","year":"2022","journal-title":"Eur. Heart J. Suppl."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"B4","DOI":"10.1016\/j.jacc.2024.09.210","article-title":"TCT-174 High Bleeding Risk and Outcomes in Acute Coronary Syndrome After Percutaneous Coronary Intervention With Versus Without Cangrelor","volume":"84","author":"Chaturvedi","year":"2024","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/432\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T16:56:26Z","timestamp":1760028986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/18\/3\/432"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,19]]},"references-count":97,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3]]}},"alternative-id":["ph18030432"],"URL":"https:\/\/doi.org\/10.3390\/ph18030432","relation":{},"ISSN":["1424-8247"],"issn-type":[{"type":"electronic","value":"1424-8247"}],"subject":[],"published":{"date-parts":[[2025,3,19]]}}}